• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Studies Give Mixed Results About Taking Fish Oil and Vitamin D
(CHICAGO) — Taking fish oil or vitamin D? Big studies give long-awaited answers on who does and does not benefit from these popular nutrients. Fish oil taken by healthy people, at a dose found in many supplements, showed no clear ability to lower heart or cancer risks. Same for vitamin D. But higher amounts of a purified, prescription fish oil slashed heart problems and heart-related deaths among people with high triglycerides, a type of fat in the blood, and other risks for heart disease. Doctors cheered the results and said they could suggest a new treatment option for hundreds of thousands of patients like these. ...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: MARILYNN MARCHIONE / AP Tags: Uncategorized onetime Supplements Source Type: news

Prescription Doses of Fish Oil May Lower Heart Attack and Stroke Risk
Omega-3 fatty acids, abundant in fish oil, are known to be good for the heart. Studies have shown that people who eat more fish rich in these fats have lower rates of heart problems and less risk of dying from heart disease compared to those who eat less. Those data have fueled a booming business in over-the-counter fish oil supplements. In a new study published in the New England Journal of Medicine, and presented at the American Heart Association annual meeting, researchers report that a highly purified version of omega-3 fats, called icosapent ethyl, can lower the risk of a number of heart-related events, including hear...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthytime Heart Disease omega-3 Source Type: news

Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
Publication date: Available online 2 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Marc P Bonaca, J Antonio Gutierrez, Christopher Cannon, Robert Giugliano, Michael Blazing, Jeong-Gun Park, Jennifer White, Andrew Tershakovec, Eugene BraunwaldSummaryBackgroundPolyvascular disease and type 2 diabetes are each associated with increased cardiovascular risk, but whether these risks are additive is unknown. In this exploratory analysis of a randomised trial, we explored the long-term cardiovascular risk associated with polyvascular disease, type 2 diabetes, and their combination in patients with acute corona...
Source: The Lancet Diabetes and Endocrinology - November 3, 2018 Category: Endocrinology Source Type: research

Statins associated with improvement of rare lung disease
This study suggests that oral statin therapy may be a new approach for patients with autoimmune pulmonary alveolar proteinosis.AUTHORSThe study ’s co-senior authors are Dr. Elizabeth Tarling of UCLA and Dr. Bruce Trapnell of Children’s Hospital Medical Center of Cincinnati, Ohio. Other authors are listed in the journal article.JOURNALThe study was  published in the journal Nature Communications. FUNDINGThe National Institutes of Health funded the research.Learn more about the  cardiovascular research theme at UCLA. 
Source: UCLA Newsroom: Health Sciences - August 17, 2018 Category: Universities & Medical Training Source Type: news

Severe Symptoms, but a Truly Treatable Disease
​BY NOURA MAHDI; DARRON LEWIS; JEREMY OSBORNE; & AHMED RAZIUDDIN, MDA 73-year-old man was brought to the emergency department from his nursing home for rectal bleeding and anemia. The patient mentioned he had had episodes of bright red rectal bleeding and constipation for a few months. A colonoscopy had been done prior to the visit, which revealed a large intestine tumor and biopsy confirming adenocarcinoma. He was awaiting an appointment with his surgeon.The patient reported bloody rectal leakage, and a CBC done at the nursing home showed a hemoglobin level of 7.2. He also complained of dyspnea but denied any other ...
Source: The Case Files - March 20, 2018 Category: Emergency Medicine Tags: Blog Posts Source Type: research

This Cholesterol Drug Combination Might Lower Your Risk of Death, Study Finds
(ORLANDO) — A newer cholesterol drug, used with older statin medicines, modestly lowered heart risks and deaths in a big study of heart attack survivors that might persuade insurers to cover the pricey treatment more often. Results on the drug, Praluent, were announced Saturday at an American College of Cardiology conference in Florida. It’s the first time a cholesterol-lowering drug has reduced deaths since statins such as Lipitor and Crestor came out decades ago. “It’s the ultimate outcome; it’s what matters to patients,” said study leader Dr. Philippe Gabriel Steg of Hospital Bichat i...
Source: TIME: Health - March 10, 2018 Category: Consumer Health News Authors: Marilyn Marchione / AP Tags: Uncategorized APH healthytime medicine onetime Source Type: news

HIV-positive adults are under-treated for cardiovascular problems compared to those without HIV
This study provides evidence that U.S. policymakers and professional societies should focus on improving the quality of the cardiovascular care that people who are HIV-positive receive.AUTHORSStudy authors are Dr. Joseph Ladapo, Dr. Adam Richards, Cassandra DeWitt, Nina Harawa, Steven Shoptaw, Dr. William Cunningham and Dr. John Mafi, all of UCLA. Mafi is also associated with Rand Corporation.JOURNALThestudy is published in the Journal of the American Heart Association.FUNDINGGrants from the National Heart, Lung and Blood Institute, National Institute on Minority Health and Health Disparities, and National Institute of Men...
Source: UCLA Newsroom: Health Sciences - November 22, 2017 Category: Universities & Medical Training Source Type: news

Heart attack and stroke patients prescribed statin medication upon discharge have better outcomes
(Intermountain Medical Center) Patients with a prior history of heart attacks or stroke have better outcomes when cholesterol-lowering medications are used after they're discharged from the hospital, according to a new study from the Intermountain Medical Center Heart Institute in Salt Lake City.
Source: EurekAlert! - Medicine and Health - November 12, 2017 Category: International Medicine & Public Health Source Type: news

Predictors of functional outcome and hemorrhagic complications in acute ischemic stroke patients treated with intravenous thrombolysis - A retrospective analysis 
.
Predictors of functional outcome and hemorrhagic complications in acute ischemic stroke patients treated with intravenous thrombolysis - A retrospective analysis
. Int J Clin Pharmacol Ther. 2017 Oct 26;: Authors: Zhao Q, Shan W, Liu L, Fu X, Liu P, Hu Y Abstract Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) within 4.5 hours is an effective and routine therapy for acute ischemic stroke (AIS). The purpose of the study was to identify predictors of functional outcome at 3 months and hemorrhagic complications after IVT. A total of 123 AIS patients treated with in...
Source: International Journal of Clinical Pharmacology and Therapeutics - November 4, 2017 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

Statins Losing Their Luster?
STATINS HAVE NUMEROUS intriguing and potentially desirable pleiotropic anti-inflammatory effects that may clinically benefit patients undergoing cardiac surgery with/without cardiopulmonary bypass.1,2 Suggested clinical benefits include decreased postoperative morbidity (renal dysfunction, atrial fibrillation, myocardial infarction, stroke, infection) as well as decreased in-hospital mortality. While suppressing perioperative inflammation in patients undergoing cardiac surgery appears to make sense, nothing is ever as simple as it seems.
Source: Journal of Cardiothoracic and Vascular Anesthesia - September 19, 2017 Category: Anesthesiology Authors: Richa Dhawan, Mark A. Chaney Tags: Editorial Source Type: research

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Publication date: Available online 15 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Marc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, Robert P Giugliano, Prakash Deedwania, Gaetano M De Ferrari, Sabina A Murphy, Julia F Kuder, Ioanna Gouni-Berthold, Basil S Lewis, Yehuda Handelsman, Armando Lira Pineda, Narimon Honarpour, Anthony C Keech, Peter S Sever, Terje R Pedersen Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this prespecified analysis of FOURIER, we investigated ...
Source: The Lancet Diabetes and Endocrinology - September 16, 2017 Category: Endocrinology Source Type: research

Secondary prevention treatment after acute stroke in older South Asian, Chinese and other Canadians: a retrospective data analysis.
Abstract BACKGROUND: Little is known about whether there are differences in medication use between older patients of Chinese descent, those of South Asian descent and other Canadian patients after acute ischemic or primary intracerebral hemorrhagic stroke. The aim of this population-based study was to evaluate potential ethnic differences in secondary prevention pharmacotherapy after acute stroke. METHODS: Using health administrative data, we conducted a retrospective analysis of all patients aged 66 years or more admitted to hospital with acute stroke in Ontario (1997-2011) and British Columbia (1997-2009). ...
Source: cmaj - September 11, 2017 Category: General Medicine Authors: Khan NA, McAlister FA, Pilote L, Palepu A, Quan H, Hill MD, Fang J, Kapral MK Tags: CMAJ Open Source Type: research

Drug Aimed at Inflammation May Lower Risk of Heart Disease and Cancer
A milestone finding for researchers, the connection of inflammatory responses to such illnesses could open the door to new treatments.
Source: NYT Health - August 27, 2017 Category: Consumer Health News Authors: DENISE GRADY Tags: Brigham and Women's Hospital Lancet, The (Journal) Heart Lung Cancer Smoking and Tobacco Cholesterol Research Preventive Medicine Stroke Immune System Statins (Cholesterol-Lowering Drugs) Clinical Trials Methotrexate (Drug) Ridke Source Type: news

Statins Overlooked for Secondary Stroke Prevention Statins Overlooked for Secondary Stroke Prevention
A nationwide study found one-fifth of patients discontinued statins 3 to 6 months after discharge for an ischemic stroke, while another study found less than half were ever prescribed a statin upon leaving the hospital.Medscape Medical News
Source: Medscape Medical News Headlines - August 8, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Dose-Dependent Effect of Statin Pretreatment on Preventing the Periprocedural Complications of Carotid Artery Stenting Clinical Sciences
Background and Purpose—We investigated whether statin pretreatment can dose dependently reduce periprocedural complications in patients undergoing carotid artery stenting because of symptomatic carotid artery stenosis.Methods—We enrolled a consecutive series of 397 symptomatic carotid artery stenosis (≥50% stenosis on conventional angiography) treated with carotid artery stenting at 2 tertiary university hospitals over a decade. Definition of periprocedural complications included any stroke, myocardial infarction, and death within 1 month after or during the procedure. Statin pretreatment was divided into 3 categorie...
Source: Stroke - June 26, 2017 Category: Neurology Authors: Jeong-Ho Hong, Sung-Il Sohn, Jaehyuk Kwak, Joonsang Yoo, Hyuk Won Chang, O-Ki Kwon, Cheolkyu Jung, Inyoung Chung, Hee-Joon Bae, Ji Sung Lee, Moon-Ku Han Tags: Stent, Ischemic Stroke Original Contributions Source Type: research

Pages: 1  2  3  4  5  6  7